[Progress in genetic research on primary pulmonary hypertension]
1Center of Genetics and Prenatal Diagnosis, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China. qh_wu77@163.com.
Primary pulmonary hypertension (PPH) involves genetic and environmental factors, leading to pulmonary artery hyperplasia. This review summarizes the function and mechanisms of key genes, like BMPR2, in PPH pathogenesis.
Area of Science:
- Cardiovascular Research
- Genetics and Pathogenesis
- Pulmonary Hypertension
Background:
- Primary pulmonary hypertension (PPH) is a severe obstructive lung disease.
- PPH encompasses hereditary and idiopathic pulmonary arterial hypertension.
- Both genetic predisposition and environmental factors contribute to PPH development.
Purpose of the Study:
- To review the function and mechanisms of genes implicated in PPH pathogenesis.
- To highlight the role of the TGF-β signaling pathway in PPH.
- To consolidate current knowledge on genetic factors in PPH.
Main Methods:
- Literature review of genetic associations with PPH.
- Analysis of gene functions within the TGF-β signaling pathway.
- Summary of identified genes including BMPR2, ALK1, ENG, SMAD8, NFU1, CAV1, KCNK3, and TopBP1.
Main Results:
- Several genes, particularly BMPR2, are crucial in PPH pathogenesis.
- Dysregulation of the TGF-β signaling pathway is a key mechanism.
- Specific genes like NFU1, CAV1, KCNK3, and TopBP1 also contribute to PPH.
Conclusions:
- Genetic factors play a significant role in the development of PPH.
- Understanding these gene functions aids in elucidating PPH mechanisms.
- Further research into these genetic pathways may offer therapeutic targets for PPH.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...


